Salivary alpha-synuclein (total and oligomeric form): potential biomarkers in Parkinson’s disease

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery - Tập 56 Số 1 - 2020
Hala A. Shaheen1, Sayed Sobhy1, Sherine El Mously1, Marwa Abuomira1, Mohamed H. Mansour1
1Faculty of Medicine, Fayoum University, Keman Fares Area, Fayoum City, 63611, Egypt

Tóm tắt

Abstract Background Parkinson’s disease (PD) is one of the most common degenerative diseases of the central nervous system (CNS). Alpha-synuclein (A-syn) plays a critical role in the pathogenesis of PD. The close relation between the salivary glands and the CNS could render the A-syn secretions in the saliva useful biomarkers for PD. Aim of the work To study the salivary A-syn levels in a cohort of PD Egyptian patients and to correlate these A-syn levels with the patients’ clinical data and disease severity. Patients and methods Twenty-five PD patients and 15 age- and sex-matched healthy subjects, as a control group, were enrolled. Evaluation of PD patients was performed using the Unified Parkinson’s Disease Rating Scale (UPDRS) and modified Hoehn and Yahr scale (HYS). Samples of the saliva were analyzed using the enzyme-linked immunosorbent assay (ELISA) technique for the specific anti A-syn total and anti A-syn oligomer (A-synolig). Results There was a statistically significant increase in A-synolig level and A-synolig/A-syn total ratio and a decrease in A-syn total level among PD patients. A statistically significant increase in A-synolig level was detected among patients having bradykinesia and rigidity as predominant symptoms. Also, there was a statistically significant positive correlation between A-synolig level and the disease duration. No statistically significant correlation was found between A-syn concentrations and disease severity. Conclusion Salivary A-syn total and A-synolig can be used as potential biomarkers for PD diagnosis.

Từ khóa


Tài liệu tham khảo

Oikonomou E, Paparrigopoulos T. Neuropsychiatric manifestations in Parkinson’s disease. Psychiatriki. 2015;26(2):116–30.

Atik A, Stewart T, Zhang J. Alpha-synuclein as a biomarker for Parkinson’s disease. Brain Pathol. 2016;26(3):410–8.

Fauvet B, Mbefo K, Fares B, Desobry C, Michael S, Ardah T, et al. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012;287:15345–64.

Vekrellis K, Xilouri M, Emmanouilidou E, Rideout J, Stefanis L. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015–25.

Roberts L, Brown R. Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules. 2015;5(2):282–305.

Beach G, Adler H, Sue I, Vedders L, Lue L, White Iii L, et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119(6):689–702.

Cersosimo M, Perandones C, Micheli F, Raina G, Beron A, Nasswetter G, et al. Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Mov Disord. 2011;26(1):188–90.

Devic I, Hwang H, Edgar S, Izutsu K, Presland R, Pan C, et al. Salivary a-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain. 2011;134:e178.

Vivacqua G, Latorre A, Suppa A, Nardi M, Pietracupa S, Mancinelli R, et al. Abnormal salivary total and oligomeric alpha-synuclein in Parkinson's disease. PLoS One. 2016;11(3):e0151156.

Bougea A, Koros C, Stefanis L. Salivary alpha-synuclein as a biomarker for Parkinson’s disease: a systematic review. J Neural Transm (Vienna). 2019;126(11):1373–82.

Hughes A, Daniel S, Blankson S, Lees A. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol. 1993;50(2):140–8.

Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41–7.

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020–8.

Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40(10):1529–34.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649–53.

El-Agnaf M, Salem A, Paleologou E, Curran D, Gibson J, Court A, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J. 2006;20(3):419–25.

Tokuda T, Qureshi M, Ardah M, Varghese S, Shehab S, Kasai T, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75:1766–72.

Park M, Cheon S, Bae H, Kim S, Kim J. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease. J Clin Neurol. 2011;7(4):215–22.

Bengoa-Vergniory N, Roberts R, Wade-Martins R, Alegre-Abarrategui J. Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 2017;134(6):819–38.

Fairfoul G, McGuire L, Pal S, Ironside J, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3:812–7.

Farah R, Haraty H, Salame Z, Fares Y, Ojcius DM, Said SN. Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed J. 2018;41(2):63–87.

Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499–504.

Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’sdisease. J Neuropathol Exp Neurol. 1991;50(6):743–55.

Malec-Litwinowicz M, Plewka A, Plewka D, Bogunia E, Morek M, Szczudlik A, et al. The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson’s disease. Neurol Neurochir Pol. 2018;52(2):243–51.

Shi M, Zabetian P, Hancock M, Ginghina C, Hong Z, Yearout D, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett. 2010;480:78–82.

Winner B, Jappelli R, Maji S, Desplats A, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA. 2011;108(10):4194–9.

Helwig M, Klinkenberg M, Rusconi R, Musgrove R, Majbour N, El-Agnaf O, et al. Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice. Brain. 2016;139(3):856–70.

Caughey B, Lansbury P. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267–98.

Parkkinen L, Pirttilä T, Tervahauta M, Alafuzoff I. Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology. 2005;25(4):304–14.

Frigerio R, Fujishiro H, Ahn T, Josephs K, Maraganore D, DelleDonne A, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging. 2011;32(5):857–63.

Colosimo C, Hughes A, Kilford L, Lees A. Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:852–6.

Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115(4):399–407.

Gaig C, Martí M, Ezquerra M, Cardozo A, Rey M, Tolosa E. G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatry. 2007;78(6):626–8.

Cookson M, Hardy J, Lewis P. Genetic neuropathology of Parkinson’s disease. Int J Clin Exp Pathol. 2008;1(3):217–31.

Soto C, Estrada L. Protein misfolding and neurodegeneration. Arch Neurol. 2008;65(2):184–9.

Eleuteri S, Albanese A. VPS35-based approach: a potential innovative treatment in Parkinson’s disease. Front Neurol. 2019;10:1272.

Thông tin
Thông tin xuất bản

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Tập 56 Số 1

Thông tin tác giả